Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations in ERG2

ABSTRACT Two novel isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B (MIC, 8 μg ml−1) were found to be ERG2 mutants, wherein Δ8-sterol intermediates comprised >90% of the total cellular sterol fraction. Both harbored an alteration at Thr121 in ERG2; the corresponding residue (Thr119) in Saccharomyces cerevisiae is essential for sterol Δ8-Δ7 isomerization. This constitutes the first report of C. glabrata harboring mutations in ERG2 and exhibiting reduced sensitivity to amphotericin B.

[1]  D. Kelly,et al.  Facultative Sterol Uptake in an Ergosterol-Deficient Clinical Isolate of Candida glabrata Harboring a Missense Mutation in ERG11 and Exhibiting Cross-Resistance to Azoles and Amphotericin B , 2012, Antimicrobial Agents and Chemotherapy.

[2]  Daniel S. Palacios,et al.  Amphotericin primarily kills yeast by simply binding ergosterol , 2012, Proceedings of the National Academy of Sciences.

[3]  D. Kelly,et al.  Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.

[4]  D. Kelly,et al.  A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B , 2010, Antimicrobial Agents and Chemotherapy.

[5]  M. Melhem,et al.  Mutants with heteroresistance to amphotericin B and fluconazole in Candida , 2009, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[6]  G. Fadda,et al.  Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence , 2009, PLoS pathogens.

[7]  A. Rahier,et al.  Identification of essential amino acid residues in a sterol 8,7-isomerase from Zea mays reveals functional homology and diversity with the isomerases of animal and fungal origin. , 2008, The Biochemical journal.

[8]  J. Bouchara,et al.  A Nonsense Mutation in the ERG6 Gene Leads to Reduced Susceptibility to Polyenes in a Clinical Isolate of Candida glabrata , 2008, Antimicrobial Agents and Chemotherapy.

[9]  J. Perfect,et al.  Resistance to Antifungal Agents : Mechanisms and Clinical Impact , 2007 .

[10]  C. Hennequin,et al.  Reduced Susceptibility to Polyenes Associated with a Missense Mutation in the ERG6 Gene in a Clinical Isolate of Candida glabrata with Pseudohyphal Growth , 2006, Antimicrobial Agents and Chemotherapy.

[11]  D. Loebenberg,et al.  In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.

[12]  Thierry Langer,et al.  Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening , 2005 .

[13]  G. Fadda,et al.  Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance , 2005, Antimicrobial Agents and Chemotherapy.

[14]  M. Bard,et al.  Candida glabrata erg1 Mutant with Increased Sensitivity to Azoles and to Low Oxygen Tension , 2004, Antimicrobial Agents and Chemotherapy.

[15]  D. Sanglard,et al.  Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal Agents , 2003, Antimicrobial Agents and Chemotherapy.

[16]  M. Pfaller,et al.  In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp , 2002, Antimicrobial Agents and Chemotherapy.

[17]  A. Barnes,et al.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. , 2002, The Journal of hospital infection.

[18]  G. Bonn,et al.  Histidine77, glutamic acid81, glutamic acid123, threonine126, asparagine194, and tryptophan197 of the human emopamil binding protein are required for in vivo sterol delta 8-delta 7 isomerization. , 1999, Biochemistry.

[19]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[20]  T. Sterling,et al.  Resistance to amphotericin B: emerging clinical and microbiological patterns. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  S. Kelly,et al.  Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. , 1997, FEMS microbiology letters.

[22]  D. Kelly,et al.  Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients , 1996, The Lancet.

[23]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[24]  M. Kaghad,et al.  The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae , 1996, Molecular and cellular biology.

[25]  T J Walsh,et al.  Antifungal agents: chemotherapeutic targets and immunologic strategies , 1996, Antimicrobial agents and chemotherapy.

[26]  J. Swartz,et al.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.

[27]  M. Pfaller,et al.  Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. , 1994, Diagnostic microbiology and infectious disease.

[28]  S. Kelly,et al.  Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. , 1994, FEMS microbiology letters.

[29]  J. Hargreaves,et al.  Isolation and characterization of polyene-resistant mutants from the maize smut pathogen, Ustilago maydis, defective in ergosterol biosynthesis , 1992 .

[30]  J. Bolard.  How do the polyene macrolide antibiotics affect the cellular membrane properties? , 1986, Biochimica et biophysica acta.

[31]  J. Smith,et al.  Antimicrobial susceptibility of Pneumocystis carinii in culture. , 1985, Diagnostic microbiology and infectious disease.